Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

From embedded interprofessional clinics to expanded alcohol-associated liver disease programs

Winder GS, Arab JP, Goswami Banerjee A, Bryce K, Fipps DC, Hussain F, Im G, Omary L, Patel AA, Patel S, Rubman S, Serper M,[...]

Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials

Linggi B, Azucena S, Steere B, Verstockt B, Alsoud D, Casero D, McGovern D, Chan E, Smith MI, Ungaro F, Rieder F, Aden K, Shackelton[...]

Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United States Federally Qualified Health Centers

Zhao MY, Aaronson MRM, Singh V, De Silva SR, Badiee J, May FP. Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United[...]